What Does Microdosing GLP-1 Cost?

Cost is the single biggest reason anyone microdoses a GLP-1 drug. The pitch is simple: instead of paying brand-name prices for a full therapeutic dose, you stretch a cheaper compounded vial across many small fractional doses and pay a fraction of the monthly cost. This page lays out what microdosing GLP-1 actually costs across the routes people use — and, just as importantly, what the low sticker price hides. Read it as a buyer's-guide reality check, not an endorsement: there is no FDA-approved microdose of any GLP-1 drug, and the cheapest routes are also the least regulated.

Before the numbers, one framing fact the marketing skips: a "microdose" is a self-selected amount below even the lowest FDA-approved starting dose, so it is never sold to you as a finished, approved product ¹. Every price below is therefore the price of an off-label, do-it-yourself arrangement.

The two cost worlds: brand vs compounded

There are really two price tiers, and they're far apart.

Brand-name GLP-1 drugs — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — carry list prices that, without insurance coverage, commonly land in the $500 to $1,300 per month range depending on the drug and dose. Manufacturer savings programs and cash-pay vial offers have pushed some self-pay options lower, but the headline number for an uninsured buyer is high — and that high number is precisely the pressure that created the microdosing market in the first place ².

Compounded GLP-1 — mixed by a pharmacy rather than manufactured as the branded finished drug — is the cheaper tier, which is exactly why the direct-to-consumer market for it exploded during the GLP-1 shortage ²³. Compounded semaglutide and tirzepatide from telehealth platforms commonly advertise in the $155 to $500 per month range, and a microdosing approach (drawing smaller fractional amounts from a vial) is marketed as stretching that even further. The savings are real on paper. The catch is everything that comes bundled with the compounded supply chain — which we get to below.

Where the "microdose makes it even cheaper" math comes from

The microdosing cost logic is straightforward arithmetic: if a compounded vial contains, say, several full doses' worth of drug, and you draw a small fraction each time, one vial lasts many more weeks than it would at a full therapeutic dose. Spread the vial's price across more doses and the per-week cost drops. That's the entire financial appeal, and it's why microdosing is discussed almost exclusively in the context of cost-driven compounding rather than any clinical recommendation ¹.

But the math has two leaks the pitch doesn't price in.

Leak 1 — you may be buying proportionally less benefit. GLP-1 drugs follow a dose-response curve: lower doses do less. In a semaglutide dose-ranging trial, the lowest dose produced the smallest weight loss ⁴, and tirzepatide's pivotal obesity trial showed higher doses delivering more weight loss than lower ones ⁵. A microdose sits at the very bottom of that curve — sometimes below the lowest dose ever formally studied. Paying less to get proportionally less (or, at a true microdose, possibly very little) isn't the bargain a flat "cheaper per month" makes it sound.

Leak 2 — you may be paying in risk instead of dollars. The savings on compounded product come bundled with documented sourcing and preparation problems. A pharmacovigilance analysis of compounded GLP-1 agonists using the FDA Adverse Event Reporting System (FAERS) found markedly elevated reporting odds for preparation errors (reporting odds ratio about 48.9), contamination (about 19.0), compounding issues (about 8.5), and prescribing errors (about 4.5), along with more reports of abdominal pain, cholecystitis, and hospitalization ⁶. That's a spontaneous-reporting database — association, not proof of causation — but it's exactly the signal you'd want flagged before choosing a route on price alone. "Cheaper" and "safer" are not the same axis.

The hidden line items

The advertised monthly price is rarely the whole cost. Budget honestly for:

• •Clinician visits and intake fees. A legitimate route involves a licensed clinician actually reviewing your case — telehealth platforms bundle or charge for this, and a supervised plan with your own physician adds visit costs.
• •Lab work and monitoring. Baseline and follow-up labs add cost but are part of doing this responsibly, not an optional extra.
• •Supplies. Syringes, alcohol swabs, sharps disposal — small, but real and recurring.
• •The cost of getting it wrong. If a compounded vial's concentration is uncertain and you measure a "microdose" out of it, a wrong-concentration vial can turn a microdose into a large overdose — a safety cost, not just a financial one ⁶.

The legal status is part of the price

Part of why compounded product is cheaper is that it sits outside the standardized manufacturing and quality controls of an FDA-approved drug. Compounding became widespread under shortage rules that temporarily allowed broader compounding; as those shortages resolved, the legal footing for routine compounding narrowed considerably ³. The clinical-pharmacy consensus is cautious: a position opinion on compounded incretins stresses they should be considered carefully and primarily in the context of genuine access problems — not as a casual cheaper alternative ⁷. A rock-bottom price from an unvetted source often reflects that it's the grey market, where the safety data are worst.

A sourcing-vetting checklist before you pay anything

If cost has pushed you toward a compounded or microdosing route, vet hard before you pay. Ask any provider:

• •Is a licensed clinician genuinely reviewing your case, or is it a rubber-stamp intake?
• •Is the product an FDA-approved branded drug or compounded? If compounded, which 503A or 503B pharmacy makes it — and will they name it?
• •Will they tell you the exact concentration of what they ship? (Essential if you intend to measure a fraction — and the difference between a microdose and an overdose.)
• •What monitoring, labs, and follow-up are included in the price?
• •Are there hidden intake, membership, or renewal fees on top of the advertised monthly number?

If a provider can't answer those plainly, that's a red flag — and a reason to walk, no matter how low the price. We grade providers on exactly these points on our GLP-1 microdose rankings hub.

The honest bottom line

Microdosing GLP-1 is cheaper than brand-name therapy — compounded routes commonly run $155–$500/month versus $500–$1,300/month for brand — and that gap is the entire reason the practice exists. But the low price isn't free money. The dose-response evidence says a microdose likely buys proportionally less benefit ⁴⁵, the compounded supply chain carries documented safety signals ⁶, and the cheapest sources are the least regulated ³⁷. If you proceed, do it with a qualified clinician and a legitimately sourced, known-concentration product — and treat any unusually cheap, unvetted source as the warning it is.

For the full evidence picture, start with our pillar Microdosing GLP-1: what the evidence actually shows. If you've decided to proceed, how to get microdosing tirzepatide walks through the real routes, and is compounded / microdosed GLP-1 safe covers the safety case in depth. See also microdosing tirzepatide: what the evidence actually says, and weigh the value question against low-dose vs full-dose GLP-1. Compare vetted options on the GLP-1 microdose rankings hub.